Pfizer Inc. (NYSE:PFE) Shares Acquired by Pzena Investment Management LLC

Pzena Investment Management LLC boosted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 0.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,281,709 shares of the biopharmaceutical company's stock after buying an additional 24,029 shares during the period. Pzena Investment Management LLC owned approximately 0.13% of Pfizer worth $210,733,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in PFE. Marshall Wace LLP boosted its holdings in Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock worth $150,481,000 after acquiring an additional 8,378,173 shares during the period. Swedbank AB bought a new stake in Pfizer in the first quarter valued at $172,902,000. International Assets Investment Management LLC bought a new stake in Pfizer in the third quarter valued at $146,481,000. 1832 Asset Management L.P. lifted its stake in Pfizer by 24,961.6% in the second quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company's stock valued at $69,891,000 after buying an additional 2,487,919 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its stake in shares of Pfizer by 120.7% during the third quarter. Robeco Institutional Asset Management B.V. now owns 4,498,313 shares of the biopharmaceutical company's stock valued at $130,181,000 after purchasing an additional 2,459,666 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Daiwa America raised Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They issued a "neutral" rating and a $30.00 target price for the company. Wells Fargo & Company boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $32.92.

Pfizer Stock Down 0.6 %

PFE traded down $0.16 during trading on Wednesday, hitting $24.95. The stock had a trading volume of 46,016,745 shares, compared to its average volume of 38,444,336. The company has a market capitalization of $141.36 billion, a PE ratio of 33.71, a PEG ratio of 0.79 and a beta of 0.67. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50 day simple moving average of $28.36 and a two-hundred day simple moving average of $28.61.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm's revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.17) earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.73%. The ex-dividend date is Friday, November 8th. Pfizer's payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.